Over time, pharmacological engineering enabled: Short-acting injectables (e.g., exenatide) Long-acting once-weekly injectables (liraglutide, semaglutide) Multi-target incretin therapies (tirzepatide) Oral peptide formulations and now oral small molecules The most recent breakthrough is the development of orally available GLP-1 receptor agonists, including: Orforglipron (Lilly) Elecoglipron (AstraZeneca) These compounds eliminate the need for injection and could dramatically expand accessibility and adherence in obesity and diabetes populations
This hormone, GLP-1, is released from your gut after you eat
This holistic set is ideal for stubborn teenage and adult acne, targeting the root causes while soothing and restoring your skin's barrier
The patient may experience weight loss and a loss of appetite
Subscript T and R represent the test preparation and the reference preparation for extravascular administration, respectively, while D represents the administered dose
10.1016/S0016-5085(98)70160-X Gastroenterology 44 MariM.CaballeroF.ColellA.MoralesA.CaballeriaJ.FernandezA.et al (2006)